

CORRECTION

Open Access



# Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Daniele Cretella<sup>1</sup>, Andrea Ravelli<sup>1</sup>, Claudia Fumarola<sup>1\*</sup>, Silvia La Monica<sup>1</sup>, Graziana Digiacoimo<sup>1</sup>, Andrea Cavazzoni<sup>1</sup>, Roberta Alfieri<sup>1</sup>, Alessandra Biondi<sup>1</sup>, Daniele Generali<sup>2,3</sup>, Mara Bonelli<sup>1†</sup> and Pier Giorgio Petronini<sup>1†</sup>

**Correction:** *J Exp Clin Cancer Res* 37, 72 (2018)

<https://doi.org/10.1186/s13046-018-0741-3>

Following the publication of the original article [1], the authors identified errors in Figs. 2 and 3. Blots were developed using the method with films and these errors could possibly due to incorrect film was scanned twice and/or in the wrong side and was mislabeled.

The correct figures are presented below:

---

<sup>†</sup>Mara Bonelli and Pier Giorgio Petronini contributed equally to this work.

---

The original article can be found online at <https://doi.org/10.1186/s13046-018-0741-3>.

---

\*Correspondence:

Claudia Fumarola  
claudia.fumarola@unipr.it

<sup>1</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy


<sup>2</sup>Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy

<sup>3</sup>U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare e Farmacogenomica, ASST Cremona, Cremona, Italy




© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Incorrect Figure 2




**Fig. 2** Palbociclib modulates the activation/expression of cell cycle-related proteins in a dose- and time-dependent manner. MDA-MB-231 and HCC38 cells were treated with increasing concentrations of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time (b). The expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experiments

Correct Figure 2




**Fig. 2** Palbociclib modulates the activation/expression of cell cycle-related proteins in a dose- and time-dependent manner. MDA-MB-231 and HCC38 cells were treated with increasing concentrations of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time (b). The expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experiments

Incorrect Figure 3



**Fig. 3** Palbociclib up-regulates the PI3K/AKT/mTOR pathway in TNBC cells. MDA-MB-231 and HCC38 cells were treated with increasing concentrations of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time (b). Then, the expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experiments

Correct Figure 3



**Fig. 3** Palbociclib up-regulates the PI3K/AKT/mTOR pathway in TNBC cells. MDA-MB-231 and HCC38 cells were treated with increasing concentrations of palbociclib for 24 h (a) or with a fixed drug concentration for different periods of time (b). Then, the expression of the indicated proteins was analyzed by Western blotting. Results are representative of three independent experiments

The corrections do not compromise the validity of the conclusions and the overall content of the article.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Published online: 16 April 2025

**References**

1. Cretella D, Ravelli A, Fumarola C, et al. The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells. *J Exp Clin Cancer Res.* 2018;37:72. <https://doi.org/10.1186/s13046-018-0741-3>.